Stockreport

SCYNEXIS Announces Positive Results from a Phase 1, Single Ascending Dose and Multiple Ascending Dose Study of its Second-Generation Fungerp (SCY-247)

SCYNEXIS, Inc.  (SCYX) 
Last scynexis, inc. earnings: 11/12 08:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.scynexis.com/investor-relations
PDF No safety concerns or dose limiting toxicities observed SCY-247 was able to achieve target exposures at doses lower than our first-generation fungerp Safety, tolerabil [Read more]